Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eczema
Biotech
Leo's eczema prospect hits primary endpoint in phase 2b
Leo shared phase 2b data on temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
Nick Paul Taylor
May 9, 2025 7:30am
Amgen ignites Rocket program with wins in phase 3 eczema trials
Mar 10, 2025 5:48am
Anaptys scraps atopic dermatitis asset after ph. 2 fail
Dec 11, 2024 11:02am
Amgen reports first phase 3 win for $400M eczema drug
Sep 25, 2024 5:50am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
Lilly's lebrikizumab clears eczema in people with skin of color
Mar 11, 2024 9:24am